Piotr Ozieranski

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 17

Top Topics

Cross Sectional

Kidney Transplantation

Top Venues

Globalization and health

International journal of health policy and management

This page only lists publications with an associated author ORCID identifier.

Publications

Anju Murayama, Sae Kamamoto, Hiroaki Saito, Erika Yamashita, Yosuke Suzuki, Tetsuya Tanimoto, Piotr Ozieranski, Akihhiko Ozaki
Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis. International journal of health policy and management 12 (2023)
Anju Murayama, Sae Kamamoto, Hiroaki Saito, Erika Yamashita, Yosuke Suzuki, Tetsuya Tanimoto, Piotr Ozieranski, Akihhiko Ozaki
Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis. International journal of health policy and management 12 (2023)
Anju Murayama, Sae Kamamoto, Hiroaki Saito, Erika Yamashita, Yosuke Suzuki, Tetsuya Tanimoto, Piotr Ozieranski, Akihhiko Ozaki
Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis. International journal of health policy and management 12 (2023)
Piotr Ozieranski, Eszter Saghy, Shai Mulinari
Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database. PloS one 18 (11) (2023)
Piotr Ozieranski, Hiroaki Saito, Emily Rickard, Shai Mulinari, Akihiko Ozaki
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Globalization and health 19 (1) (2023)
Emily Rickard, Emma Carmel, Piotr Ozieranski
Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis. BMJ open 13 (3) (2023)
Piotr Ozieranski, Hiroaki Saito, Emily Rickard, Shai Mulinari, Akihiko Ozaki
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Globalization and health 19 (1) (2023)
Piotr Ozieranski, Hiroaki Saito, Emily Rickard, Shai Mulinari, Akihiko Ozaki
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Globalization and health 19 (1) (2023)
Emily Rickard, Emma Carmel, Piotr Ozieranski
Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis. BMJ open 13 (3) (2023)
Evgenia Paloumpi, Piotr Ozieranski, Margaret C Watson, Matthew D Jones
Professional stakeholders' expectations for the future of community pharmacy practice in England: a qualitative study. BMJ open 13 (10) (2023)
Piotr Ozieranski, Hiroaki Saito, Emily Rickard, Shai Mulinari, Akihiko Ozaki
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Globalization and health 19 (1) (2023)
Piotr Ozieranski, Hiroaki Saito, Emily Rickard, Shai Mulinari, Akihiko Ozaki
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Globalization and health 19 (1) (2023)
Piotr Ozieranski, Luc Martinon, Pierre-Alain Jachiet, Shai Mulinari
Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe. International journal of health policy and management (2022)
Piotr Ozieranski, János György Pitter, Emily Rickard, Shai Mulinari, Marcell Csanádi
A 'patient-industry complex'? Investigating the financial dependency of UK patient organisations on drug company funding. Sociology of health & illness (2021)
Emily Rickard, Piotr Ozieranski
A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups. PloS one 16 (6) (2021)
Piotr Ozieranski, Luc Martinon, Pierre-Alain Jachiet, Shai Mulinari
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review. BMJ open 11 (12) (2021)
Piotr Ozieranski, Marcell Csanádi, Emily Rickard, Shai Mulinari
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016). BMJ open 10 (9) (2020)